Friday, 14 August 2020


Halozyme licenses $25M drug delivery technology to Roche

30 October 2018 | News

Under the terms of the agreement, HALO will receive $25M upfront, up to $160M - 165M in milestones per target and mid-single-digit royalties on net sales.

Singapore – Halozyme has out-licensed its ENHANZE drug delivery technology to Roche for the exclusive development of a new undisclosed drug target with an option to add two more within four years.

Under the terms of the agreement, HALO will receive $25M upfront, up to $160M - 165M in milestones per target and mid-single-digit royalties on net sales. It will also receive a nomination fee for each of the additional two targets.

HALO will recognize the $25M payment this quarter.

ENHANZE, based on a recombinant human hyaluronidase enzyme that temporarily degrades hyaluronan (a chain of natural sugars in the body), enables the subcutaneous administration of biologic drugs, traditionally administered intravenously.

Roche submitted a U.S. marketing application for an ENHANZE-based formulation of Herceptin in July.


Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account




Podcast

 

Survey Box

Should we be cautious of viewing COVID-19 vaccine as silver bullet?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls